Optimal inflammatory bowel disease (IBD) therapy often requires biologic medications delivered by intravenous (IV) infusion. Until recently, infusions were generally delivered in supervised hospital or outpatient clinics. As insurance companies attempt to minimize costs, IV infusions are being transitioned into patient homes. Limited data exists on the safety, effectiveness and experience of home infusion (HI) programs.